S&P 500   5,146.07 (-1.02%)
DOW   38,110.26 (-0.91%)
QQQ   440.77 (-1.03%)
AAPL   176.80 (+1.01%)
MSFT   422.75 (-1.21%)
META   515.17 (-1.53%)
GOOGL   159.10 (-0.19%)
AMZN   187.11 (-1.03%)
TSLA   172.10 (-1.43%)
NVDA   892.76 (-1.48%)
AMD   164.39 (-3.58%)
NIO   4.18 (-6.28%)
BABA   72.46 (-3.19%)
T   16.39 (-0.18%)
F   12.73 (-2.38%)
MU   124.64 (-2.25%)
GE   154.79 (-1.66%)
CGC   7.84 (-3.80%)
DIS   114.39 (-2.36%)
AMC   2.76 (-1.43%)
PFE   26.13 (-0.80%)
PYPL   65.81 (+0.02%)
XOM   123.46 (+1.37%)
S&P 500   5,146.07 (-1.02%)
DOW   38,110.26 (-0.91%)
QQQ   440.77 (-1.03%)
AAPL   176.80 (+1.01%)
MSFT   422.75 (-1.21%)
META   515.17 (-1.53%)
GOOGL   159.10 (-0.19%)
AMZN   187.11 (-1.03%)
TSLA   172.10 (-1.43%)
NVDA   892.76 (-1.48%)
AMD   164.39 (-3.58%)
NIO   4.18 (-6.28%)
BABA   72.46 (-3.19%)
T   16.39 (-0.18%)
F   12.73 (-2.38%)
MU   124.64 (-2.25%)
GE   154.79 (-1.66%)
CGC   7.84 (-3.80%)
DIS   114.39 (-2.36%)
AMC   2.76 (-1.43%)
PFE   26.13 (-0.80%)
PYPL   65.81 (+0.02%)
XOM   123.46 (+1.37%)
S&P 500   5,146.07 (-1.02%)
DOW   38,110.26 (-0.91%)
QQQ   440.77 (-1.03%)
AAPL   176.80 (+1.01%)
MSFT   422.75 (-1.21%)
META   515.17 (-1.53%)
GOOGL   159.10 (-0.19%)
AMZN   187.11 (-1.03%)
TSLA   172.10 (-1.43%)
NVDA   892.76 (-1.48%)
AMD   164.39 (-3.58%)
NIO   4.18 (-6.28%)
BABA   72.46 (-3.19%)
T   16.39 (-0.18%)
F   12.73 (-2.38%)
MU   124.64 (-2.25%)
GE   154.79 (-1.66%)
CGC   7.84 (-3.80%)
DIS   114.39 (-2.36%)
AMC   2.76 (-1.43%)
PFE   26.13 (-0.80%)
PYPL   65.81 (+0.02%)
XOM   123.46 (+1.37%)
S&P 500   5,146.07 (-1.02%)
DOW   38,110.26 (-0.91%)
QQQ   440.77 (-1.03%)
AAPL   176.80 (+1.01%)
MSFT   422.75 (-1.21%)
META   515.17 (-1.53%)
GOOGL   159.10 (-0.19%)
AMZN   187.11 (-1.03%)
TSLA   172.10 (-1.43%)
NVDA   892.76 (-1.48%)
AMD   164.39 (-3.58%)
NIO   4.18 (-6.28%)
BABA   72.46 (-3.19%)
T   16.39 (-0.18%)
F   12.73 (-2.38%)
MU   124.64 (-2.25%)
GE   154.79 (-1.66%)
CGC   7.84 (-3.80%)
DIS   114.39 (-2.36%)
AMC   2.76 (-1.43%)
PFE   26.13 (-0.80%)
PYPL   65.81 (+0.02%)
XOM   123.46 (+1.37%)

Vaccitech (VACC) Competitors

$3.33
+0.10 (+3.10%)
(As of 04/11/2024 ET)

VACC vs. BRNS, CRVS, RZLT, IFRX, PMVP, CMRX, ASRT, ETON, VAXX, and MIST

Should you be buying Vaccitech stock or one of its competitors? The main competitors of Vaccitech include Barinthus Biotherapeutics (BRNS), Corvus Pharmaceuticals (CRVS), Rezolute (RZLT), InflaRx (IFRX), PMV Pharmaceuticals (PMVP), Chimerix (CMRX), Assertio (ASRT), Eton Pharmaceuticals (ETON), Vaxxinity (VAXX), and Milestone Pharmaceuticals (MIST). These companies are all part of the "pharmaceutical preparations" industry.

Vaccitech vs.

Vaccitech (NASDAQ:VACC) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, profitability, valuation, risk, earnings, media sentiment and dividends.

Vaccitech has a beta of -0.4, suggesting that its share price is 140% less volatile than the S&P 500. Comparatively, Barinthus Biotherapeutics has a beta of -0.52, suggesting that its share price is 152% less volatile than the S&P 500.

In the previous week, Barinthus Biotherapeutics had 1 more articles in the media than Vaccitech. MarketBeat recorded 2 mentions for Barinthus Biotherapeutics and 1 mentions for Vaccitech. Barinthus Biotherapeutics' average media sentiment score of 1.44 beat Vaccitech's score of -1.08 indicating that Barinthus Biotherapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Vaccitech Negative
Barinthus Biotherapeutics Positive

Vaccitech received 13 more outperform votes than Barinthus Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Barinthus Biotherapeutics an outperform vote while only 70.83% of users gave Vaccitech an outperform vote.

CompanyUnderperformOutperform
VaccitechOutperform Votes
17
70.83%
Underperform Votes
7
29.17%
Barinthus BiotherapeuticsOutperform Votes
4
100.00%
Underperform Votes
No Votes

26.1% of Vaccitech shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 6.0% of Vaccitech shares are held by insiders. Comparatively, 8.0% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Barinthus Biotherapeutics has a net margin of 0.00% compared to Vaccitech's net margin of -409.18%. Vaccitech's return on equity of -23.41% beat Barinthus Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Vaccitech-409.18% -23.41% -20.85%
Barinthus Biotherapeutics N/A -35.19%-30.80%

Vaccitech has higher revenue and earnings than Barinthus Biotherapeutics. Vaccitech is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vaccitech$13.42M9.56$5.34M-$1.43-2.33
Barinthus Biotherapeutics$800K162.00-$73.35M-$1.92-1.73

Vaccitech currently has a consensus price target of $7.63, indicating a potential upside of 128.98%. Barinthus Biotherapeutics has a consensus price target of $8.00, indicating a potential upside of 140.24%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Vaccitech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vaccitech
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Barinthus Biotherapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Barinthus Biotherapeutics beats Vaccitech on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VACC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VACC vs. The Competition

MetricVaccitechPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$128.36M$5.70B$5.07B$7.77B
Dividend YieldN/A2.85%2.96%3.87%
P/E Ratio-2.3317.61247.7819.30
Price / Sales9.56353.022,385.34105.54
Price / Cash19.3033.3035.8032.13
Price / Book0.515.114.704.40
Net Income$5.34M$123.81M$104.61M$215.04M
7 Day Performance-9.26%0.06%-0.59%-0.61%
1 Month Performance25.19%-0.84%-0.30%0.15%
1 Year Performance43.53%10.00%18.65%11.93%

Vaccitech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BRNS
Barinthus Biotherapeutics
2.6185 of 5 stars
$2.37
-3.3%
$8.00
+237.6%
N/A$91.39M$800,000.00-1.23107Short Interest ↓
Gap Down
CRVS
Corvus Pharmaceuticals
2.8447 of 5 stars
$1.86
flat
$6.63
+256.2%
+25.8%$91.21MN/A-3.2628Short Interest ↓
RZLT
Rezolute
3.3072 of 5 stars
$2.29
-5.4%
$8.67
+278.5%
+30.7%$90.73MN/A-2.0857Analyst Report
IFRX
InflaRx
2.7773 of 5 stars
$1.54
+1.3%
$11.67
+657.6%
-69.1%$90.68M$70,000.00-1.7962Short Interest ↑
PMVP
PMV Pharmaceuticals
2.0753 of 5 stars
$1.79
+0.6%
$6.00
+235.2%
-61.2%$92.08MN/A-1.2363Analyst Report
News Coverage
Positive News
CMRX
Chimerix
4.2915 of 5 stars
$1.01
-3.8%
$8.00
+692.1%
-17.5%$90.10M$320,000.00-1.1072Positive News
Gap Up
ASRT
Assertio
2.3161 of 5 stars
$0.93
-1.1%
$5.50
+491.7%
-84.9%$88.30M$152.07M-0.2353Positive News
ETON
Eton Pharmaceuticals
2.1037 of 5 stars
$3.68
-1.9%
$10.00
+171.7%
-6.3%$94.54M$31.64M-122.6730Short Interest ↓
VAXX
Vaxxinity
2.3159 of 5 stars
$0.69
-2.8%
$7.00
+912.1%
-76.0%$87.66M$70,000.00-1.5487Gap Up
MIST
Milestone Pharmaceuticals
2.3177 of 5 stars
$1.80
-1.6%
$11.20
+522.2%
-55.9%$95.67M$1M-1.2947Positive News

Related Companies and Tools

This page (NASDAQ:VACC) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners